迈瑞医疗亮相RSNA2025 携超高端超声北美首秀

Core Insights - The 111th Radiological Society of North America (RSNA 2025) conference showcased Mindray Medical's high-end ultrasound product Resona A20, highlighting the innovation capabilities of Chinese medical device companies in the advanced imaging sector [1][3] Product Innovation - Resona A20 is the first ultrasound device to achieve super-resolution blood flow imaging in clinical settings, enhancing traditional imaging capabilities from millimeter to micrometer levels, which is crucial for early tumor diagnosis [4] - The product has received certifications from the EU and FDA since its domestic launch in 2023, gaining recognition in key global markets, including successful installations in prestigious hospitals [6] Market Performance - Mindray Medical's international revenue in the medical imaging sector reached 61% in the first three quarters of 2025, with high-end ultrasound product revenues doubling, driving business growth [8] - Resona A20 has been installed in top hospitals in China and renowned medical institutions in Germany and the UK, establishing strong partnerships with leading healthcare organizations [8] Global Expansion - Mindray Medical has solidified its global market presence, ranking third in global ultrasound market share as of 2024, with a high single-digit percentage in overseas markets [8] - The successful debut of Resona A20 at the RSNA conference marks a significant milestone for Mindray Medical's expansion into the North American market, indicating a new phase of development [10]